Covid-19 Impact on Plasma Therapy in the Healthcare Industry
Coronavirus is a large family of viruses known for diseases ranging from the common cold to even more serious diseases such as Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). The virus has spread to almost all regions of the world, affecting both developed and developing countries which have heavily affected pharmaceutical and biotechnology companies. The epidemic spread rapidly across the globe within three months and was characterized by the VHO as a pandemic on March 11, 2020. According to the Worldometers.info statistics, as of 27th April 2020, there are 3,064,225 people are already affected and 211,537 patients are died due to the coronavirus. There are currently no approved specific antiviral agents targeting the new virus, while some drugs are still under investigation, including remdesivir and lopinavir / ritonavir. It is urgent to look for an alternative strategy to treat COVID-19, especially among severe patients, as an effective vaccine and specific antiviral medicines are not available till the date. Plasma medications are produced from human blood plasma (plasma). Plasma can be obtained from administration of whole blood (recovered plasma) or apheresis procedures (plasma source). The source is plasma a wide range of medicinal therapies products used for treatment and the prevention of various treatment-causing injuries and diseases often associated with a protein deficiency state. Convalescent Plasma Therapy (CP), a classic adaptive immunotherapy, has been used in the prevention and treatment of many infectious diseases for over a century. In the past two decades, CP therapy has been successfully used in the treatment of the 2009 SARS, MERS and H1N1 pandemic with satisfactory efficacy and safety. In 2014, the World Health Organization (WHO) recommended the use
